Brokerages forecast that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will announce $5.97 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Karyopharm Therapeutics’ earnings, with estimates ranging from $50,000.00 to $12.00 million. The business is scheduled to announce its next quarterly earnings results on Tuesday, August 14th.
On average, analysts expect that Karyopharm Therapeutics will report full-year sales of $17.03 million for the current fiscal year, with estimates ranging from $10.00 million to $25.00 million. For the next financial year, analysts forecast that the firm will post sales of $17.50 million per share, with estimates ranging from $7.93 million to $40.98 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, May 10th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.11). The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $4.59 million.
Shares of Karyopharm Therapeutics traded up $0.04, reaching $16.99, during midday trading on Tuesday, according to Marketbeat Ratings. 404,423 shares of the company traded hands, compared to its average volume of 843,300. Karyopharm Therapeutics has a 52 week low of $8.00 and a 52 week high of $20.39. The stock has a market cap of $846.95 million, a P/E ratio of -6.05 and a beta of 3.73.
In related news, insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction dated Monday, April 9th. The stock was sold at an average price of $12.48, for a total value of $124,800.00. Following the transaction, the insider now owns 723,510 shares of the company’s stock, valued at approximately $9,029,404.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christopher Brett Primiano sold 2,000 shares of Karyopharm Therapeutics stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $18.01, for a total value of $36,020.00. Following the completion of the transaction, the executive vice president now directly owns 675 shares in the company, valued at approximately $12,156.75. The disclosure for this sale can be found here. Insiders sold a total of 62,000 shares of company stock worth $1,029,920 in the last three months. 13.26% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Teacher Retirement System of Texas purchased a new position in Karyopharm Therapeutics in the 4th quarter worth about $115,000. MetLife Investment Advisors LLC purchased a new position in Karyopharm Therapeutics in the 4th quarter worth about $146,000. Two Sigma Investments LP increased its stake in Karyopharm Therapeutics by 76.8% in the 4th quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock worth $233,000 after purchasing an additional 10,520 shares in the last quarter. UBS Group AG increased its stake in Karyopharm Therapeutics by 761.8% in the 1st quarter. UBS Group AG now owns 19,632 shares of the company’s stock worth $264,000 after purchasing an additional 17,354 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in Karyopharm Therapeutics in the 1st quarter worth about $269,000. 61.90% of the stock is currently owned by hedge funds and other institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.